Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HY6725 in Healthy Participants
NCT07262281Phase 1Recruiting
- Sponsor
- Newsoara Biopharma
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HY-6725 in asthma and chronic obstructive pulmonary disease (COPD), sponsored by Newsoara Biopharma. Primary endpoints: Treatment-Emergent Adverse Events at Day 150, Serious Adverse Events at Day 150 and 3 more. Started Feb 2026; status: recruiting.
02
Drugs
HY-6725
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07262281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07262281.